86 related articles for article (PubMed ID: 18754885)
1. Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2.
Kasukabe T; Okabe-Kado J; Honma Y
Cancer Sci; 2008 Aug; 99(8):1693-8. PubMed ID: 18754885
[TBL] [Abstract][Full Text] [Related]
2. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.
Kasukabe T; Okabe-Kado J; Kato N; Sassa T; Honma Y
Breast Cancer Res; 2005; 7(6):R1097-110. PubMed ID: 16457690
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
4. Vitamin K2 and cotylenin A synergistically induce monocytic differentiation and growth arrest along with the suppression of c-MYC expression and induction of cyclin G2 expression in human leukemia HL-60 cells.
Maniwa Y; Kasukabe T; Kumakura S
Int J Oncol; 2015 Aug; 47(2):473-80. PubMed ID: 26046133
[TBL] [Abstract][Full Text] [Related]
5. Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
Kasukabe T; Okabe-Kado J; Kato N; Honma Y; Kumakura S
Int J Oncol; 2015 Feb; 46(2):841-8. PubMed ID: 25405645
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.
Kasukabe T; Okabe-Kado J; Haranosono Y; Kato N; Honma Y
Int J Oncol; 2013 Feb; 42(2):767-75. PubMed ID: 23255002
[TBL] [Abstract][Full Text] [Related]
7. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
Böhm A; Aichberger KJ; Mayerhofer M; Herrmann H; Florian S; Krauth MT; Derdak S; Samorapoompichit P; Sonneck K; Vales A; Gleixner KV; Pickl WF; Sperr WR; Valent P
Eur J Clin Invest; 2009 May; 39(5):395-405. PubMed ID: 19320940
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategy using phenotypic modulation of cancer cells by differentiation-inducing agents.
Honma Y; Akimoto M
Cancer Sci; 2007 Nov; 98(11):1643-51. PubMed ID: 17645578
[TBL] [Abstract][Full Text] [Related]
9. Oligosaccharides from human milk induce growth arrest via G2/M by influencing growth-related cell cycle genes in intestinal epithelial cells.
Kuntz S; Kunz C; Rudloff S
Br J Nutr; 2009 May; 101(9):1306-15. PubMed ID: 19079835
[TBL] [Abstract][Full Text] [Related]
10. Sesamin, a lignan of sesame, down-regulates cyclin D1 protein expression in human tumor cells.
Yokota T; Matsuzaki Y; Koyama M; Hitomi T; Kawanaka M; Enoki-Konishi M; Okuyama Y; Takayasu J; Nishino H; Nishikawa A; Osawa T; Sakai T
Cancer Sci; 2007 Sep; 98(9):1447-53. PubMed ID: 17640297
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Law M; Forrester E; Chytil A; Corsino P; Green G; Davis B; Rowe T; Law B
Cancer Res; 2006 Jan; 66(2):1070-80. PubMed ID: 16424043
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels.
Ghayad SE; Bieche I; Vendrell JA; Keime C; Lidereau R; Dumontet C; Cohen PA
Cancer Sci; 2008 Oct; 99(10):1992-2003. PubMed ID: 19016759
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-mediated G1 arrest involves regulation of the Cdk inhibitor Sic1 in Saccharomyces cerevisiae.
Zinzalla V; Graziola M; Mastriani A; Vanoni M; Alberghina L
Mol Microbiol; 2007 Mar; 63(5):1482-94. PubMed ID: 17302822
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer.
Fechner G; Classen K; Schmidt D; Hauser S; Müller SC
Urology; 2009 Mar; 73(3):665-8; discussion 668-9. PubMed ID: 19081609
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition.
Zhao YM; Zhou Q; Xu Y; Lai XY; Huang H
Acta Pharmacol Sin; 2008 Apr; 29(4):481-8. PubMed ID: 18358095
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
18. Phorbol ester-induced monocytic differentiation is associated with G2 delay and down-regulation of cdc25 expression.
Hass R; Gunji H; Hirano M; Weichselbaum R; Kufe D
Cell Growth Differ; 1993 Mar; 4(3):159-66. PubMed ID: 8466854
[TBL] [Abstract][Full Text] [Related]
19. Induction of differentiation of myeloid leukemia cells in primary culture in response to lithocholic acid acetate, a bile acid derivative, and cooperative effects with another differentiation inducer, cotylenin A.
Horie A; Akimoto M; Tsumura H; Makishima M; Taketani T; Yamaguchi S; Honma Y
Leuk Res; 2008 Jul; 32(7):1112-23. PubMed ID: 18242698
[TBL] [Abstract][Full Text] [Related]
20. [Ectopic expression of cyclin G2 inhibits cell proliferation in HeLa cancer cell line].
Tian YL; Liu FR; Liu J; Jiang L; Luo Y; Zhang X
Ai Zheng; 2002 Jun; 21(6):577-81. PubMed ID: 12452053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
